GlassScriptPhysician profile
Hannah Hamilton
NPI 1932753357
$5,342.38
in general payments reported to CMS, 2019-2025
53 companies · $1,205 in 2025
The $1,205 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.54 · 2022: $595 · 2023: $1,562 · 2024: $1,969 · 2025: $1,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,661 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,660.69 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $655.62 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $375.07 | 2022-2025 | Libtayo, Lynozyfic |
| Janssen Biotech, INC. | $282.72 | 2022-2025 | Erleada, Darzalex, Balversa |
| Celgene Corporation | $246.58 | 2023-2025 | Reblozyl |
| Incyte Corporation | $244.30 | 2022-2025 | Monjuvi, Pemazyre, Zynyz |
| Merck Sharp & Dohme LLC | $224.59 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $200.03 | 2022-2025 | Enhertu, Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $192.05 | 2022-2025 | |
| Exelixis INC. | $180.40 | 2022-2025 | Cabometyx |
| Ipsen Biopharmaceuticals, INC | $177.14 | 2022-2025 | Onivyde, Somatuline Depot |
| Beigene USA, INC. | $170.95 | 2023-2025 | Brukinsa, Tevimbra |
| Astrazeneca Pharmaceuticals LP | $152.19 | 2022-2025 | Calquence, Lynparza, Imfinzi |
| Pharmaessentia USA Corporation | $130.55 | 2023-2025 | Besremi |
| Pfizer INC. | $122.52 | 2023-2025 | |
| Deciphera Pharmaceuticals INC. | $114.60 | 2022-2025 | Qinlock, Romvimza, Tgct |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $111.19 | 2023-2025 | Orserdu |
| Genentech USA, INC. | $109.09 | 2023-2025 | Polivy, Tecentriq, Phesgo |
| Genzyme Corporation | $108.43 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $97.51 | 2023-2024 | Ultomiris, Soliris |
| Array Biopharma INC | $96.04 | 2023-2025 | Braftovi, Mektovi, Xalkori |
| Seagen INC. | $90.91 | 2022-2023 | Padcev, Adcetris, Tukysa |
| Astellas Pharma US INC | $90.71 | 2024-2025 | Xtandi |
| Takeda Pharmaceuticals U.S.A., INC. | $86.05 | 2024-2025 | Ninlaro, Fruzaqla |
| Karyopharm Therapeutics INC. | $85.35 | 2022-2025 | Xpovio |
| Eisai INC. | $84.90 | 2022-2024 | |
| Beone Medicines USA, INC. | $81.21 | 2025 | Brukinsa, Tevimbra |
| Glaxosmithkline, LLC. | $73.04 | 2023-2025 | Ojjaara, Blenrep, Shingrix |
| Abbvie INC. | $67.82 | 2024-2025 | |
| Sobi, INC | $64.81 | 2022-2024 | |
| Taiho Oncology, INC. | $47.48 | 2023-2024 | |
| Emd Serono, INC. | $42.38 | 2023-2025 | Bavencio |
| Mirati Therapeutics, INC. | $41.76 | 2023 | Krazati |
| Pharmacosmos Therapeutics INC. | $40.29 | 2023-2024 | Monoferric, Cosela |
| Aveo Pharmaceuticals, INC. | $39.20 | 2023-2024 | Fotivda |
| Sun Pharmaceutical Industries INC. | $39.01 | 2023-2024 | Yonsa, Odomzo |
| Adc Therapeutics America, INC. | $35.78 | 2022-2023 | |
| G1 Therapeutics, INC. | $32.45 | 2023 | Cosela |
| Genmab U.S., INC. | $30.87 | 2023-2024 | Epkinly |
| E.R. Squibb & Sons, L.L.C. | $30.45 | 2022-2025 | Camzyos |
| Morphosys, US INC. | $25.38 | 2021-2023 | Monjuvi |
| Csl Behring | $25.14 | 2025 | Privigen |
| Amgen INC. | $23.19 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $19.35 | 2023 | Imbruvica |
| Kite Pharma, INC. | $18.70 | 2025 | Yescarta |
| Azurity Pharmaceuticals, INC. | $17.73 | 2025 | Vivimusta |
| Servier Pharmaceuticals LLC | $16.99 | 2024 | |
| Coherus Oncology, INC. | $16.30 | 2022 | |
| Puma Biotechnology, INC. | $15.25 | 2023 | Nerlynx |
| Global Blood Therapeutics, INC. | $15.02 | 2022 | |
| Apellis Pharmaceuticals, INC. | $13.58 | 2024 | Empaveli |
| Sumitomo Pharma America, INC. | $13.51 | 2024 | Orgovyx |
| Lilly USA, LLC | $13.38 | 2024 | Retevmo, Jaypirca, Verzenio |
| Myovant Sciences INC. | $12.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.